NuVasive To Expands Global Presence, Pediatric Portfolio With Ellipse Buy
This article was originally published in Clinica
Executive Summary
On Jan. 5, NuVasive said it agreed to buy Ellipse in a deal that is expected to be complete by the end of February. NuVasive will pay an additional $30 million in 2017 if Ellipse's portfolio meets certain revenue targets.
You may also be interested in...
Earnings Winners And Losers: BSX, BCR, NUVA, NVCR
Several big names in medtech announced their second-quarter sales and earnings in late July and early August. Here are some of the companies that impressed investors and others that raised some doubts.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.